Abstract
In a nasal vaccine against influenza, the activation of natural killer T (NKT) cells by intranasal coadministration of α-galactosylceramide (α-GalCer) can potently enhance protective immune responses. The results of this study show that the NKT cell-activated nasal vaccine can induce an effective cross-protection against different strains of influenza virus, including H5 type. To analyze the mechanism of NKT cell activation by this nasal vaccine, we prepared fluorescence-labeled α-GalCer by which we detect a direct interaction between NKT cells and α-GalCer-stored dendritic cells in nasal mucosa-associated tissues. Accordingly, although very few NKT cells exist at mucosa, the nasal vaccination induced a localized increase in NKT cell population, which is partly dependent on CXCL16/CXCR6. Furthermore, we found that NKT cell activation stimulates mucosal IgA production by a mechanism that is dependent on interleukin (IL)-4 production. These results strengthen the basis of nasal vaccination via NKT cell activation, which can induce immune cross-protection.
| Original language | English |
|---|---|
| Pages (from-to) | 208-218 |
| Number of pages | 11 |
| Journal | Mucosal Immunology |
| Volume | 1 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2008 May |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
Cite this
Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses. / Kamijuku, H.; Nagata, Y.; Jiang, X.; Ichinohe, T.; Tashiro, T.; Mori, K.; Taniguchi, M.; Hase, Kouji; Ohno, H.; Shimaoka, T.; Yonehara, S.; Odagiri, T.; Tashiro, M.; Sata, T.; Hasegawa, H.; Seino, K. I.
In: Mucosal Immunology, Vol. 1, No. 3, 05.2008, p. 208-218.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses
AU - Kamijuku, H.
AU - Nagata, Y.
AU - Jiang, X.
AU - Ichinohe, T.
AU - Tashiro, T.
AU - Mori, K.
AU - Taniguchi, M.
AU - Hase, Kouji
AU - Ohno, H.
AU - Shimaoka, T.
AU - Yonehara, S.
AU - Odagiri, T.
AU - Tashiro, M.
AU - Sata, T.
AU - Hasegawa, H.
AU - Seino, K. I.
PY - 2008/5
Y1 - 2008/5
N2 - In a nasal vaccine against influenza, the activation of natural killer T (NKT) cells by intranasal coadministration of α-galactosylceramide (α-GalCer) can potently enhance protective immune responses. The results of this study show that the NKT cell-activated nasal vaccine can induce an effective cross-protection against different strains of influenza virus, including H5 type. To analyze the mechanism of NKT cell activation by this nasal vaccine, we prepared fluorescence-labeled α-GalCer by which we detect a direct interaction between NKT cells and α-GalCer-stored dendritic cells in nasal mucosa-associated tissues. Accordingly, although very few NKT cells exist at mucosa, the nasal vaccination induced a localized increase in NKT cell population, which is partly dependent on CXCL16/CXCR6. Furthermore, we found that NKT cell activation stimulates mucosal IgA production by a mechanism that is dependent on interleukin (IL)-4 production. These results strengthen the basis of nasal vaccination via NKT cell activation, which can induce immune cross-protection.
AB - In a nasal vaccine against influenza, the activation of natural killer T (NKT) cells by intranasal coadministration of α-galactosylceramide (α-GalCer) can potently enhance protective immune responses. The results of this study show that the NKT cell-activated nasal vaccine can induce an effective cross-protection against different strains of influenza virus, including H5 type. To analyze the mechanism of NKT cell activation by this nasal vaccine, we prepared fluorescence-labeled α-GalCer by which we detect a direct interaction between NKT cells and α-GalCer-stored dendritic cells in nasal mucosa-associated tissues. Accordingly, although very few NKT cells exist at mucosa, the nasal vaccination induced a localized increase in NKT cell population, which is partly dependent on CXCL16/CXCR6. Furthermore, we found that NKT cell activation stimulates mucosal IgA production by a mechanism that is dependent on interleukin (IL)-4 production. These results strengthen the basis of nasal vaccination via NKT cell activation, which can induce immune cross-protection.
UR - http://www.scopus.com/inward/record.url?scp=42149161737&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=42149161737&partnerID=8YFLogxK
U2 - 10.1038/mi.2008.2
DO - 10.1038/mi.2008.2
M3 - Article
C2 - 19079180
AN - SCOPUS:42149161737
VL - 1
SP - 208
EP - 218
JO - Mucosal Immunology
JF - Mucosal Immunology
SN - 1933-0219
IS - 3
ER -